Headquartered in Palo Alto, CA Fiscal year ends December NASDAQ: GH guardanthealth.com
Guardant Health is a precision oncology company focused on transforming cancer care through advanced blood-based (liquid biopsy) and tissue tests, real-world data, and AI analytics. Founded in 2012, the company's products span all stages of cancer care: its Shield blood test is designed for colorectal cancer screening to detect cancer early; its oncology portfolio, anchored by the Guardant360 platform, supports treatment selection for patients with advanced cancer and monitoring for recurrence in early-stage cancer; and its Biopharma & Data segment provides pharmaceutical companies with genomic data and analytics to accelerate drug development. The company trades on Nasdaq under the ticker GH and generates revenue across four segments: Oncology, Biopharma and Data, Screening, and Licensing and Other. Updated
Pre-Market Stock Futures: Futures are trading lower as we get to wrap up a busy week, and what a week it has been. After a solid mid-week rally on Wednesday that had…
Pre-Market Stock Futures: Futures are trading lower on Tuesday, but the technology tsunami continued on Monday, as all major indices dipped into the red early on news that Iran was halting the…
Thursday's top analyst upgrades and downgrades included DocuSign, Etsy, Guardant Health, International Paper, Johnson Controls, Kosmos Energy, Levi Strauss, Snowflake, Tesla, Topgolf Calloway Brands, WW International and XPO.
Tuesday's top analyst upgrades and downgrades included Broadcom, Caterpillar, CVS Health, Guardant Health, Marvell Technology, Nutrien, Paramount Global, RingCentral, SoFi Technologies, UnitedHealth Group and Workday.
Friday's top analyst upgrades and downgrades included Advanced Micro Devices, Asana, Etsy, Exact Sciences, Guardant Health, Hilton Worldwide, Meta Platforms, MongoDB, Salesforce, ServiceNow, Sysco and Teladoc Health.
Friday's premarket trading session was picking up where Thursday's regular session ended.
Tuesday's additional analyst upgrades and downgrades included Carvana, Exxon Mobil, Horizon Therapeutics, Norfolk Southern, Principal Financial, Under Armour and Ventas.
Tuesday's top analyst upgrades and downgrades included Antero Resources, Apple, Caesars Entertainment, Clarivate, Coinbase Global, Continental Resources, Electronic Arts, EQT, Goldman Sachs, Hewlett Packard Enterprise, Morgan Stanley, Netflix, Roblox, Twitter, UnitedHealth and…
Wednesday’s top analyst upgrades and downgrades included Alliance Data, AvalonBay, Boston Properties, Bruker, Camden Properties and CBRE.
Guardant Health is a precision oncology company focused on transforming cancer care through advanced blood-based (liquid biopsy) and tissue tests, real-world data, and AI analytics.
The Wall Street consensus 12-month price target for GH is $202.24.
